PE20081798A1 - Derivados piperidina y metodos de uso de los mismos - Google Patents
Derivados piperidina y metodos de uso de los mismosInfo
- Publication number
- PE20081798A1 PE20081798A1 PE2008000406A PE2008000406A PE20081798A1 PE 20081798 A1 PE20081798 A1 PE 20081798A1 PE 2008000406 A PE2008000406 A PE 2008000406A PE 2008000406 A PE2008000406 A PE 2008000406A PE 20081798 A1 PE20081798 A1 PE 20081798A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- compounds
- methods
- heteroaryl
- aryl
- Prior art date
Links
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical class C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- MZAGXDHQGXUDDX-JSRXJHBZSA-N (e,2z)-4-ethyl-2-hydroxyimino-5-nitrohex-3-enamide Chemical compound [O-][N+](=O)C(C)C(/CC)=C/C(=N/O)/C(N)=O MZAGXDHQGXUDDX-JSRXJHBZSA-N 0.000 abstract 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 229940122355 Insulin sensitizer Drugs 0.000 abstract 1
- 239000000883 anti-obesity agent Substances 0.000 abstract 1
- 229940125708 antidiabetic agent Drugs 0.000 abstract 1
- 239000003472 antidiabetic agent Substances 0.000 abstract 1
- 229940125710 antiobesity agent Drugs 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical compound OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
SE REFIERE A COMPUESTOS DERIVADOS DE PIPERIDINA DE FORMULA (I) DONDE R1 ES ARILO(C6-C14), HETEROARILO, ALQUILO(C1-C12), CICLOALQUILO(C3-C10), ENTRE OTROS; X ES -C(O)-, -C(NOR3)-, ENTRE OTROS, DONDE R3 ES H, ALQUILO(C1-C12), ARILO(C6-C14), CH2CF3, ENTRE OTROS; R2 ES HETEROARILO DE 5 A 6 MIEMBROS OPCIONALMENTE SUSTITUIDO CON HALO, OH, OCF3, NO2, ENTRE OTROS; R12 Y R13 SON CADA UNO ALQUILO(C1-C12), OH, O-ALQUILO(C1-C12) O F; M1 Y M2 SON CADA UNO CH, CF O N; Y ES -CH2-, -C(O)-, -C(S)-, ENTRE OTROS; Z ES ALQUILENO; a Y b SON CADA UNO DE 0 A 2; n Y p SON CADA UNO DE 1 A 3. SON COMPUESTOS PREFERIDOS LOS DE FORMULA (i), (ii), ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA QUE COTIENE UN AGENTE ANTIDIABETICO ADICIONAL TAL COMO UNA SULFONILUREA, UN SENSIBILIZADOR DE INSULINA, UN SECRETAGOGO DE INSULINA, UN AGENTE ANTIOBESIDAD, ENTRE OTROS. DICHOS COMPUESTOS SON UTILES EN EL TRATAMIENTO DE DIABETES, TOLERANCIA ALTERADA A LA GLUCOSA, DOLOR
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90471807P | 2007-03-02 | 2007-03-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20081798A1 true PE20081798A1 (es) | 2008-12-18 |
Family
ID=39590883
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2008000406A PE20081798A1 (es) | 2007-03-02 | 2008-02-28 | Derivados piperidina y metodos de uso de los mismos |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20100093692A1 (es) |
| EP (1) | EP2136805A2 (es) |
| JP (1) | JP2010520199A (es) |
| CN (1) | CN101674831A (es) |
| AR (1) | AR065494A1 (es) |
| CA (1) | CA2679807A1 (es) |
| CL (1) | CL2008000594A1 (es) |
| MX (1) | MX2009009417A (es) |
| PE (1) | PE20081798A1 (es) |
| TW (1) | TW200840571A (es) |
| WO (1) | WO2008108957A2 (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7820816B2 (en) | 2006-08-23 | 2010-10-26 | Teva Pharmaceutical Industries Ltd. | Process for the synthesis of CMHTP and intermediates thereof |
| WO2010101246A1 (ja) * | 2009-03-05 | 2010-09-10 | 塩野義製薬株式会社 | Ｎｐｙ ｙ５受容体拮抗作用を有するピペリジンおよびピロリジン誘導体 |
| US8829020B2 (en) | 2009-07-16 | 2014-09-09 | Mallinckrodt Llc | Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers |
| US8785440B2 (en) | 2009-09-04 | 2014-07-22 | Biogen Idec Ma, Inc. | Bruton's tyrosine kinase inhibitors |
| PH12012501385A1 (en) * | 2010-01-22 | 2014-10-22 | Taiho Pharmaceutical Co Ltd | Piperazine compound having a pgds inhibitory effect |
| AR091273A1 (es) * | 2012-06-08 | 2015-01-21 | Biogen Idec Inc | Inhibidores de pirimidinil tirosina quinasa |
| WO2015023675A2 (en) | 2013-08-12 | 2015-02-19 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
| CN103408486A (zh) * | 2013-09-09 | 2013-11-27 | 桂林理工大学 | 一种4-吡啶甲醇的制备方法 |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| WO2015095391A1 (en) | 2013-12-17 | 2015-06-25 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| LT3862003T (lt) * | 2013-12-17 | 2023-12-27 | Boehringer Ingelheim Vetmedica Gmbh | Sglt-2 inhibitorius, skirtas naudoti taikant medžagų apykaitos sutrikimo gydymą kačių šeimos gyvūnams |
| CN104059036B (zh) * | 2014-07-09 | 2015-12-02 | 厦门大学 | 一种5-[（二甲氨基）甲基]-2-呋喃甲醇的合成方法 |
| EP3169315B1 (en) | 2014-07-17 | 2020-06-24 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
| CN105315267B (zh) * | 2014-07-30 | 2019-06-04 | 江苏恩华药业股份有限公司 | 一种酰胺类衍生物及其应用 |
| EP3209282A4 (en) | 2014-10-20 | 2018-05-23 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
| KR20180132059A (ko) * | 2016-02-25 | 2018-12-11 | 아셰뉴론 에스아 | 피페라진 유도체의 거울상이성질체들을 분리하는 방법 |
| FR3052452B1 (fr) * | 2016-06-10 | 2018-06-22 | Les Laboratoires Servier | Nouveaux derives de piperidinyle, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| BR112018075284A2 (pt) * | 2016-06-10 | 2019-03-19 | Les Laboratoires Servier | derivados de piperidinila substituída por (hetero)arila, processo para sua preparação e composições farmacêuticas contendo-os |
| FR3061177B1 (fr) * | 2016-12-28 | 2019-09-27 | Les Laboratoires Servier | Nouveaux derives piperidinyles hetero(aryle)-substitues, procede pour leur preparation et compositions pharmaceutiques les contenant |
| FR3052451B1 (fr) * | 2016-06-10 | 2018-06-22 | Les Laboratoires Servier | Nouveaux derives de piperidinyle hetero(aryl)-substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| CN110049976A (zh) | 2016-07-21 | 2019-07-23 | 比奥根Ma公司 | 布鲁顿氏酪氨酸激酶抑制剂的琥珀酸盐形式和组合物 |
| US20250152585A1 (en) * | 2022-02-16 | 2025-05-15 | Duke Street Bio Limited | Pharmaceutical compound |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20020507A1 (es) * | 2000-10-17 | 2002-06-25 | Schering Corp | Compuestos no-imidazoles como antagonistas del receptor histamina h3 |
| CA2473232C (en) * | 2002-01-11 | 2011-03-15 | Abbott Laboratories | Histamine-3 receptor ligands for diabetic conditions |
| WO2004066960A2 (en) * | 2003-01-28 | 2004-08-12 | Schering Corporation | Combination of h1, h3 and h4 receptor antagonists for treatment of allergic and non-allergic pulmonary inflammation, congestion and allergic rhinitis |
| PL1615909T3 (pl) * | 2003-04-23 | 2009-01-30 | Glaxo Group Ltd | Pochodne piperazyny i ich zastosowanie w leczeniu chorób neurologicznych i psychicznych |
| EP1902046B1 (en) * | 2005-06-20 | 2009-12-02 | Schering Corporation | Piperidine derivatives useful as histamine h3 antagonists |
| KR20080081321A (ko) * | 2005-12-21 | 2008-09-09 | 쉐링 코포레이션 | Ｈ3 길항제/역 작용제 및 식욕 억제제의 조합물 |
| JP2009521452A (ja) * | 2005-12-21 | 2009-06-04 | シェーリング コーポレイション | コレステロール降下剤およびｈ３受容体アンタゴニスト／逆アゴニストを使用する非アルコール性脂肪性肝疾患の処置 |
-
2008
- 2008-02-27 CL CL200800594A patent/CL2008000594A1/es unknown
- 2008-02-27 CA CA002679807A patent/CA2679807A1/en not_active Abandoned
- 2008-02-27 AR ARP080100804A patent/AR065494A1/es not_active Application Discontinuation
- 2008-02-27 WO PCT/US2008/002590 patent/WO2008108957A2/en not_active Ceased
- 2008-02-27 CN CN200880014555A patent/CN101674831A/zh active Pending
- 2008-02-27 JP JP2009551712A patent/JP2010520199A/ja not_active Withdrawn
- 2008-02-27 EP EP08714243A patent/EP2136805A2/en not_active Withdrawn
- 2008-02-27 MX MX2009009417A patent/MX2009009417A/es unknown
- 2008-02-27 TW TW097106880A patent/TW200840571A/zh unknown
- 2008-02-27 US US12/527,499 patent/US20100093692A1/en not_active Abandoned
- 2008-02-28 PE PE2008000406A patent/PE20081798A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2010520199A (ja) | 2010-06-10 |
| AR065494A1 (es) | 2009-06-10 |
| CN101674831A (zh) | 2010-03-17 |
| MX2009009417A (es) | 2009-09-11 |
| CA2679807A1 (en) | 2008-09-12 |
| WO2008108957A2 (en) | 2008-09-12 |
| TW200840571A (en) | 2008-10-16 |
| EP2136805A2 (en) | 2009-12-30 |
| CL2008000594A1 (es) | 2008-09-05 |
| US20100093692A1 (en) | 2010-04-15 |
| WO2008108957A3 (en) | 2009-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20081798A1 (es) | Derivados piperidina y metodos de uso de los mismos | |
| ECSP045369A (es) | Derivados de n-[fenil(piperidin-2-il)metil]benzamida, su preparacion y su aplicacion en terapeutica | |
| AR068756A1 (es) | Compuestos peptidicos, formulacion farmaceutica y sus usos como moduladores del virus de la hepatitis c | |
| AR058073A1 (es) | Derivados de imidazol 5-il-pirimidina, procesos de obtencion, composiciones farmaceuticas y usos | |
| AR034282A1 (es) | Derivados de difenilazetidinona, medicamentos que contienen estos compuestos, procedimiento para su preparacion, y su utilizacion para la preparacion de medicamentos | |
| AR061548A1 (es) | 3-aminopirrolidino-4-lactamas sustituidas como inhibidoras de dipeptidilpeptidasa iv (dpp-iv), composiciones farmaceuticas que las comprenden y el uso de las mismas en el tratamiento de la diabetes ii. | |
| AR065913A1 (es) | Derivados de glicosido bencilico, composicion y combinacion farmaceutica y uso | |
| DE60310564D1 (de) | Injizierbare depotformulierung enthaltend iloperidonkrystalle | |
| AR030230A1 (es) | Derivados de acilfenilurea, procedimiento para su preparacion y su empleo en la preparacion de medicamentos | |
| AR047928A1 (es) | Derivados de tetrahidropiridoindol | |
| PE20090820A1 (es) | Derivados de piperidina/piperazina | |
| AR059339A1 (es) | Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene | |
| AR065806A1 (es) | Derivados de quinolina, procesos para su preparacion, composiciones farmaceuticas que los contienen y usos para el tratamiento de la artritis reumatoidea. | |
| PE20121336A1 (es) | Nuevos compuestos triciclicos | |
| NI200800169A (es) | Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor | |
| PE46499A1 (es) | Derivados de 6-fenilpiridil-2-amina | |
| PE20090966A1 (es) | Terapia de combinacion de un anticuerpo anti-cd20 de tipo ii con un agente activo anti-bcl-2 | |
| AR055060A1 (es) | Derivados de n-(piridin-2-il)-sulfonamida | |
| NI200800175A (es) | Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento de abuso y adicción de sustancias. | |
| AR064471A1 (es) | Macrociclos inhibidores selectivos del factor de coagulacion viia, composiciones farmaceuticas que los comprenden y uso de los mismos como agentes anticoagulantes. | |
| SV2002000522A (es) | Agosnistas adrenergicos beta3 ref. x-13921 | |
| BRPI0510080B8 (pt) | combinação farmacêutica e seu uso | |
| BRPI0308513B8 (pt) | micronizado cristalino de brometo de tiotrópio, processo para sua preparação, uso do mesmo, composição farmacêutica, pó para inalação, processo para sua preparação e cápsula que o contém | |
| PE20120648A1 (es) | Compuestos de 4-isopropilfenilglucitol como inhibidores de sglt1 | |
| UY29234A1 (es) | Derivados de adamantano, composiciones farmacéuticas que los contienen, procedimientos de preparación de ambos y aplicaciones. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |